Bristol-Myers Squibb is the first company to take advantage of Symyx Solubility Services, the latter's suite of client-directed and collaborative research services for the life sciences. These services allow clients to access Symyx’s installed base of parallel experimentation and testing capabilities through packaged offerings for solubility studies, polymorph screening, salt selection, co-crystallisation, API stability in liquid and solid formulations, excipient compatibility, organic synthesis and process optimisation.
'Symyx Research is continuing to transform its offerings into packaged, smaller scope and easily accessible solutions,' said Richard Boehner, president of Symyx Research. 'Symyx Research Services combines our industry-leading research capabilities with real-time data analysis to deliver results on demand, freeing companies from internal capability constraints while substantially reducing the cost of R&D. We are pleased to enter this agreement with Bristol-Myers Squibb to provide solubility research services which will help them achieve a greater level of R&D efficiency.'
